NEWS IN BRIEF

Grid picks Catalent to make mAb for solid tumours

By Flora Southey contact

- Last updated on GMT

GettyImages/daizuoxin
GettyImages/daizuoxin

Related tags: Cancer, Immune system, Lung cancer

Grid Therapeutics has selected Catalent Pharma Solutions to develop and manufacture its antibody candidate to treat solid tumours.

Under the agreement, Catalent will use its GPEx technology to develop the cell line for Grid, and perform development activities through to drug manufacturing.

Catalent’s Rob Gustines told us Grid will be responsible for the commercialisation of the mAb.

“Catalent’s role is to support the development of the antibody for Grid Therapeutics, who will determine the future of the programme’s commercialisation,” ​Gustines told us.

The project – sponsored by Grid – will be undertaken at Catalent’s Madison, Wisconsin-based manufacturing site.

IgG mAb

Grid identifies its tumour immunoglobulin G (IgG) antibodies from patients with early stage cancer.

“The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis,” ​said Grid.

Grid’s lead candidate is the first human derived targeted immunotherapy for cancer.

Last month, Catalent announced​ it would buy Cook Pharmica to expand its biologics, cell culture manufacturing and packaging capabilities.

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars